<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185143</url>
  </required_header>
  <id_info>
    <org_study_id>ANODYNE-2</org_study_id>
    <nct_id>NCT03185143</nct_id>
  </id_info>
  <brief_title>Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea</brief_title>
  <official_title>Randomized, Double-Blind, and Placebo-Controlled Study to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination Versus Sumatriptan in the Acute Treatment of Migraine With Nausea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allodynic Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allodynic Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen&#xD;
      combination to sumatriptan in the acute treatment of migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening visit, outpatient treatment of a moderate or severe&#xD;
      migraine attack with a single dose of the study drug within 8 weeks, and End-of-Study Visit&#xD;
      2-7 days after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients having no headache pain at 2 hours.</measure>
    <time_frame>2 hours</time_frame>
    <description>Measured by asking the patients to self-report the current status of their headache pain on a four-point Likert scale (i.e., 0=none, 1=mild, 2=moderate, 3=severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients having the absence of the most bothersome migraine-associated symptom at 2 hours.</measure>
    <time_frame>2 hours</time_frame>
    <description>The most bothersome migraine-associated symptom is prospectively identified at baseline. It is measured by asking the patients to self-report the current status of their associated symptom as present or absent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients having the absence of nausea, photophobia, phonophobia, and neck/shoulder pain at 2 hours.</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Measured by asking the patients to self-report the current status of their associated symptoms as present or absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who used rescue medications within 24 hours.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who are &quot;sustained pain-free&quot; at 24-hours and 48-hours.</measure>
    <time_frame>48 hours.</time_frame>
    <description>Defined as having no headache pain at 2 hours after the dose, with no use of rescue medication and no relapse of headache pain within 24 hours (24-hour sustained pain-free) or 48 hours (48-hour sustained pain-free) after administration of the investigational drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who had headache pain relapse within 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Defined as the return of headache of any severity within 48 hours after administration of the investigational drug, when the patient was pain-free at 2 hours after the administration of the investigational drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who experienced adverse events</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Migraine With and Without Aura</condition>
  <arm_group>
    <arm_group_label>Naltrexone and Acetaminophen Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and Acetaminophen Combination</intervention_name>
    <description>Treat a single Qualified Migraine attack.</description>
    <arm_group_label>Naltrexone and Acetaminophen Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 100 mg</intervention_name>
    <description>One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.</description>
    <arm_group_label>Sumatriptan 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18 to 65 years of age.&#xD;
&#xD;
          2. History of migraine with or without aura according to the International Classification&#xD;
             of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with&#xD;
             first migraine prior to age 50.&#xD;
&#xD;
          3. Migraine-associated nausea with â‰¥half the migraine attacks.&#xD;
&#xD;
          4. 2 - 8 migraines per month in each of the previous 3 months.&#xD;
&#xD;
          5. The patient is able to complete study questionnaires, comply with the study&#xD;
             requirements and restrictions, and willing to provide written informed consent and&#xD;
             authorize HIPAA.&#xD;
&#xD;
          6. The female patient who is premenopausal or postmenopausal less than 1 year, or have&#xD;
             not had surgical sterilization (i.e., tubal ligation, partial or complete&#xD;
             hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit&#xD;
             to using 2 methods of adequate and reliable contraception throughout the study and for&#xD;
             28 days after taking the last dose of the study drug (e.g., barrier with additional&#xD;
             spermicidal, intra-uterine device, hormonal contraception). Male patients must be&#xD;
             surgically sterile or commit to the use of 2 different methods of birth control during&#xD;
             the study and for 28 days after the study.ice, hormonal contraception).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient in the opinion of the investigator may have medication-overuse headaches&#xD;
             (as defined by ICHD - 3 beta criteria for medication-overuse headache) during the&#xD;
             preceding 3 months.&#xD;
&#xD;
          2. The patient in the opinion of the investigator has chronic migraine (as defined by&#xD;
             ICHD - 3 beta criteria for chronic migraine) during the preceding 3 months.&#xD;
&#xD;
          3. History of cluster headaches or neurologically complicated migraine (hemiplegic,&#xD;
             basilar, retinal, ophthalmoplegic).&#xD;
&#xD;
          4. Initiation or change in medications with possible migraine prophylactic effects during&#xD;
             3 months before inclusion into the trial (E.g., calcium channel blockers, tricyclic&#xD;
             antidepressants, beta-blockers, or Botox).&#xD;
&#xD;
          5. Use of opiates or barbiturates more than 3 days per month.&#xD;
&#xD;
          6. Any concurrent medical or psychiatric condition, this includes, but is not limited to&#xD;
             chronic unstable debilitating diseases, significant renal or hepatic impairment.&#xD;
&#xD;
          7. The patient has a history within the previous 3 years of abuse of any drug,&#xD;
             prescription, illicit, or alcohol.&#xD;
&#xD;
          8. The Female patient is pregnant or breast-feeding. The Male patient is not practicing 2&#xD;
             different methods of birth control with their partner during the study, and for 28&#xD;
             days after the investigational drug last dose or will not remain abstinent during the&#xD;
             study, and for 28 days after the last dose.&#xD;
&#xD;
          9. The patient has known-hypersensitivity reaction to any of the components of the&#xD;
             investigational drug.&#xD;
&#xD;
         10. Consumption of analgesic medication or muscle relaxants (including all&#xD;
             benzodiazepines) for other conditions on a regular basis.&#xD;
&#xD;
         11. The patient has used emergency care treatment more than 3 times in the previous 6&#xD;
             months.&#xD;
&#xD;
         12. The patient has participated in another study with an investigational drug within 30&#xD;
             days prior to randomization and/or plan to participate during the study.&#xD;
&#xD;
         13. The patient has a history of congenital heart disease, cardiac arrhythmias, or&#xD;
             cardiovascular disease, e.g., ischemic heart disease (e.g., stable angina pectoris,&#xD;
             unstable angina, vasospastic angina, myocardial infarction or silent myocardial&#xD;
             ischemia), cerebrovascular syndromes (e.g., strokes of any type or transient ischemic&#xD;
             attacks), peripheral vascular disease, ischemic bowel disease, or Raynaud syndrome.&#xD;
&#xD;
         14. Uncontrolled hypertension (sitting &gt;160 mmHg systolic pressure or &gt;95mmHg diastolic&#xD;
             pressure).&#xD;
&#xD;
         15. The patient, in the investigator's opinion, is likely to have unrecognized&#xD;
             cardiovascular or cerebrovascular disease.&#xD;
&#xD;
         16. History of epilepsy. Allergy to sulfonamides.&#xD;
&#xD;
         17. Consumption of monoamine oxidase inhibitor (MAOI) drug, tricyclic antidepressant,&#xD;
             selective serotonin reuptake inhibitor (SSRI) or Serotonin Noradrenaline Reuptake&#xD;
             Inhibitor (SNRI).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette C. Toledano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allodynic Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annette C. Toledano, M.D.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

